Reports of recent clinical trial data from ASCO 2012
In Brief
Already
known
EGFR-TKIs
are superior to first-line chemotherapy in
the treatment of EGFR mutation-associated
lung cancer.
What this
study showed
When compared
to optimal chemotherapy in the first-line
treatment of EGFR mutation-associated lung
cancer, afatinib shows similar benefit to
that seen with gefitinib and erlotinib.
Next steps
Afatinib will
be compared to gefitinib in the ongoing LUX-Lung
7 randomized Phase IIb trial.
